Use of sympathomimetic amines in shock.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001794:Blood Pressure; D004298:Dopamine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D007545:Isoproterenol / Q000009:adverse effects / Q000494:pharmacology; D008616:Mephentermine / Q000494:pharmacology; D008680:Metaraminol / Q000494:pharmacology; D008729:Methoxamine / Q000009:adverse effects / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D012769:Shock / Q000188:drug therapy*; D013566:Sympathomimetics / Q000009:adverse effects / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D011941:Receptors, Adrenergic; D013566:Sympathomimetics; D008680:Metaraminol; D008729:Methoxamine; D007545:Isoproterenol; D008616:Mephentermine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine